3BP-3940:靶向FAP的环肽诊疗一体化药物临床前开发
该临床前研究评估了新型FAP靶向环肽3BP-3940的亲和力、选择性、体内分布及治疗效果。3BP-3940对FAP具有高亲和力和特异性,在HEK-FAP异种移植瘤中持续摄取,177Lu标记后显著抑制肿瘤生长,小鼠和迷你猪正常组织摄取极低。
要点
- 3BP-3940对FAP具有高亲和力和特异性
- 177Lu标记的3BP-3940在HEK-FAP模型中显著抑制肿瘤生长
- 小鼠和迷你猪正常组织中摄取极低
核心结论
- 3BP-3940是 promising 的FAP靶向诊疗一体化药物,支持其临床用于癌症患者的成像和放射性药物治疗。
研究设计与样本
- 临床前研究:通过生化试验评估3BP-3940的效力和选择性,在小鼠和迷你猪中评估生物分布,在HEK-FAP小鼠模型中验证治疗效果。
主要发现
- 3BP-3940对FAP表现出高亲和力和特异性,在HEK-FAP异种移植瘤中持续摄取。
- 177Lu标记的3BP-3940导致强烈的肿瘤生长抑制。
- 3BP-3940在小鼠和迷你猪正常组织中摄取极低。
临床怎么用
- 3BP-3940可作为FAP靶向的成像和放射性药物治疗候选药物,已有在named-patient基础上治疗癌症患者的经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) is highly expressed in the tumor microenvironment of many cancer types. Since the discovery of the FAP inhibitor series, which provided high-contrast images in patients, many radiolabeled FAP-targeting agents have been developed, with the cyclic peptide FAP-2286 currently being the most advanced theranostic compound in clinical development. Here, we introduce a novel peptide, 3BP-3940, which has been used to treat patients with cancer on a named-patient basis. Methods: The potency and selectivity of 3BP-3940 were evaluated in biochemical assays. Its biodistribution was assessed in mice and minipigs, and therapeutic efficacy was demonstrated in the HEK-FAP mouse model. Results: 3BP-3940 exhibited high affinity and specificity for FAP, with persistent uptake in HEK-FAP xenograft tumors, leading to strong tumor growth inhibition when radiolabeled with 177Lu. 3BP-3940 showed minimal uptake in normal tissues of mice and minipigs. Conclusion: These findings support the clinical use of 3BP-3940 as a promising FAP-targeting agent for both imaging and radiopharmaceutical therapy in patients with cancer.
引用
- Zboralski D, Osterkamp F, von Hacht JL, et al. Preclinical Development of 3BP-3940, a Fibroblast Activation Protein-Targeted Cyclic Peptide-Based Radiotheranostic for Imaging and Therapy. J Nucl Med. 2026. PMID: 41571429. doi:10.2967/jnumed.125.271452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。